全文获取类型
收费全文 | 383篇 |
免费 | 21篇 |
专业分类
404篇 |
出版年
2022年 | 4篇 |
2021年 | 7篇 |
2020年 | 2篇 |
2019年 | 8篇 |
2018年 | 3篇 |
2017年 | 7篇 |
2016年 | 10篇 |
2015年 | 21篇 |
2014年 | 8篇 |
2013年 | 20篇 |
2012年 | 16篇 |
2011年 | 28篇 |
2010年 | 11篇 |
2009年 | 9篇 |
2008年 | 25篇 |
2007年 | 18篇 |
2006年 | 23篇 |
2005年 | 14篇 |
2004年 | 16篇 |
2003年 | 15篇 |
2002年 | 14篇 |
2001年 | 11篇 |
2000年 | 9篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1992年 | 7篇 |
1991年 | 5篇 |
1990年 | 9篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 3篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有404条查询结果,搜索用时 0 毫秒
291.
De Bonis Maria De Paolis Elisa Onori Maria Elisabetta Mazzuccato Giorgia Gatto Antonio Ferrara Pietro Ferraro Pietro Manuel Urbani Andrea Minucci Angelo 《Molecular biology reports》2021,48(4):3303-3311
Molecular Biology Reports - Pathogenic variants (PVs) in CYP24A1 gene are associated with Idiopathic Infantile Hypercalcemia disease (IIH). The identification of CYP24A1 PVs can be a useful tool... 相似文献
292.
293.
Human NORs show correlation between transcriptional activity, DNase I sensitivity, and hypomethylation 总被引:1,自引:0,他引:1
Active human ribosomal gene clusters (NORs) are distinguishable from inactive ones by silver staining. By sequentially applying deoxyribonuclease I (DNase I)-directed in situ nick-translation and silver staining to fixed chromosome preparations, we found that active NORs are more sensitive to DNase I than inactive ones. Use of the two restriction isoschizomeres MspI and HpaII to modify the nick-translation technique showed that active NORs are significantly less methylated than inactive ones. Taken as a whole, our results indicate that ribosomal gene activity, DNase I sensitivity, and DNA methylation are closely interrelated. 相似文献
294.
Mohammed Akhter Hossain Feng Lin Soude Zhang Tania Ferraro Ross A. Bathgate Geoffrey W. Tregear John D. Wade 《International journal of peptide research and therapeutics》2006,12(3):211-215
In the equine industry, pregnancy loss during the third trimester constitutes a large percentage of fetal and neonatal mortality and represents a major financial loss and time investment for the breeder. Early identification of placental insufficiency would, in some cases, make it possible to sustain the pregnancy through medical intervention. Recent work suggests that relaxin is a valuable clinical tool for diagnosing placental insufficiency and monitoring treatment efficacy in mares. Relaxin is a polypeptide member of the insulin superfamily that consists of a two-chain structure and three disulfide bonds in a disposition identical to that of insulin. It is typically produced in the ovary during pregnancy and has primary roles in maintaining mammalian pregnancy and facilitating the delivery of the young via remodelling of the reproductive tract. The placenta is the primary source of relaxin in the mare during pregnancy. Its primary structure has been determined and shown to be the smallest of the known mammalian relaxins. It consists of a 20 residue A-chain and a 28-residue B-chain. To undertake detailed biophysical and biological characterization of the peptide, its chemical synthesis was undertaken using regioselective disulfide formation methods. The synthetic equine relaxin showed typical α-helical structure under physiological conditions. The peptide was found to bind to the relaxin receptor, LGR7, in vitro, and its binding affinity was found to be higher than that of the “gold standard”, porcine relaxin, and similar to that of the human relaxin-2 (H2 relaxin). 相似文献
295.
Striatal adenosine–cannabinoid receptor interactions in rats over‐expressing adenosine A2A receptors 下载免费PDF全文
296.
297.
Ferraro Alberto Farina Ilenia Race Marco Colangelo Francesco Cioffi Raffaele Fabbricino Massimiliano 《Reviews in Environmental Science and Biotechnology》2019,18(3):453-471
Reviews in Environmental Science and Bio/Technology - The present work aims to provide a comprehensive review of the experimental studies focusing on municipal solid waste incineration fly-ash (FA)... 相似文献
298.
299.
300.
Antonio Gutiérrez Leyre Bento Antonia Maria Bautista-Gili Francesc Garcia Jordi Martinez-Serra Blanca Sanchez Clara Martorell Jordi Gines Lucia Garcia Eva Gimeno Mariana Ferraro Raquel Del Campo Joan Bargay Albert Perez Javier Vercher Miguel Scaff Ana Pacheco Carmen Ballester Florencia Garcia Rafael Ramos Antonio Salar Joan Besalduch 《PloS one》2015,10(4)
DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there have been no benefits in terms of survival. When treating malignancies RDI is important to consider but there is little published information on DLBCL. The purpose of this study was to analyze the differential prognostic impact of RDI in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. From January 2001 to August 2013 we included DLBCL patients homogenously treated with R-CHOP21 or R-CHOP14, with or without radiotherapy, at University Hospital Son Espases, Hospital Son Llatzer of Palma and Hospital del Mar of Barcelona (N = 157). In order to avoid selection bias the patients were retrospectively identified from the Pathology Department and Pharmacy registries. Median follow-up was 68 months. There was no difference in the response or survival between the two cohorts. In the R-CHOP21 group, both a reduction higher than 15% in RDI (RR 7.41) and R-IPI (RR 2.99) were independently associated with OS. However, a reduction higher than 15% in RDI (RR 4.41) was only noted for PFS. In the R-CHOP14 group, NCCN-IPI (RR 7.09) and B-symptoms (RR 5.37) for OS; AA stage III-IV (RR 6.26) and bulky disease (RR 4.05) for PFS. There was a trend towards a higher rate of RDI reduction observed in the R-CHOP14 group but it only made an impact in the R-CHOP21 group. We conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival, but only if RDI reductions are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid RDI reductions. 相似文献